Enhanced function of immuno-isolated islets in diabetes therapy byco-encapsulation with an anti-inflammatory drug

Biomaterials

Volumn 34, Issue 23, 2013, Pages 5792-5801

  Dang, Tram T ^a,b,c   Thai, Anh V ^b,c   Cohen, Joshua ^d   Slosberg, Jeremy E ^b,c   Siniakowicz, Karolina ^d   Doloff, Joshua C ^b,c   Ma, Minglin ^b,c   Hollister Lock, Jennifer ^d   Tang, Katherine M ^b,c   Gu, Zhen ^b,c   Cheng, Hao ^a,b   Weir, Gordon C ^d   Langer, Robert ^a,b   Anderson, Daniel G ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti inflammatory drugs; Curcumin; Diabetes; Encapsulated islets; Fibrotic overgrowth; Host response

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CURCUMIN; ENCAPSULATED ISLETS; FIBROTIC OVERGROWTH; HOST RESPONSE;

BIOLOGICAL MATERIALS; DRUG PRODUCTS; DRUG THERAPY; GRAFTS; MEDICAL PROBLEMS; RAT CONTROL;

ENCAPSULATION;

ALGINIC ACID; ALPHA SMOOTH MUSCLE ACTIN; CD19 ANTIGEN; CD68 ANTIGEN; CD74 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 1; CURCUMIN; DEXAMETHASONE; GLUCOSE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYDROGEL; IMMUNE RESPONSE; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LONGEVITY; MALE; MICROCAPSULE; MICROENCAPSULATION; MICROTECHNOLOGY; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAPSULES; CATHEPSINS; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SMALL MOLECULE LIBRARIES;

RATTUS;

EID: 84877797407     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.04.016     Document Type: Article

References (54)

1. Kuhtreiber W.M., Lanza R.P., Chick W.L. Cell encapsulation technology and therapeutics 1999, Birkhauser, Boston.
2. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210(4472):908-910.
3. Soon-Shiong P., Feldman E., Nelson R., Heintz R., Yao Q., Yao Z., et al. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci. 1993, 90(12):5843-5847.
4. Calafiore R., Basta G., Luca G., Lemmi A., Montanucci M.P., Calabrese G., et al. Microencapsulated pancreatic isletallografts into nonimmunosuppressed patients with type 1 diabetes. Diabetes Care 2006, 29(1):137-138.
5. Tuch B.E., Keogh G.W., Williams L.J., Wu W., Foster J.L., Vaithilingam V., et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009, 32(10):1887-1889.
6. De Groot M., Schuurs T.A., van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. JSurg Res. 2004, 121(1):141-150.
7. Van Schilfgaarde R., De Vos P. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. JMol Med 1999, 77(1):199-205.
8. Fritschy W.M., Vos P., Groen H., Klatter F.A., Pasma A., Wolters G.H.J., et al. The capsular overgrowth on microencapsulated pancreatic islet grafts in streptozotocin and autoimmune diabetic rats. Transpl Int 1994, 7(4):264-271.
9. Wu P., Grainger D.W. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006, 27(11):2450-2467.
10. Labhasetwar V., Levy R.J. Implants for site-specific drug delivery. JAppl Biomater 2004, 2:211-212.
11. Singarayar S., Kistler P.M., De Winter C., Mond H. Acomparative study of the action of dexamethasone sodium phosphate and dexamethasone acetate in steroid-eluting pacemaker leads. Pacing Clin Electrophysiol 2005, 28(4):311-315.
12. Friedl K.E. Corticosteroid modulation of tissue responses to implanted sensors. Diabetes Technol Ther 2004, 6(6):898-901.
13. Schneider B.L., Schwenter F., Pralong W.F., Aebischer P. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther 2003, 7(4):506-514.
14. Zhang W.J., Marx S.K., Laue C., Hyder A., Juergensen A., Bickel M., et al. HOE 077 reduces fibrotic overgrowth around the barium alginate microcapsules. Transplant Proc 2000, 32:206-209.
15. Tappy L., Randin D., Vollenweider P., Vollenweider L., Paquot N., Scherrer U., et al. Mechanisms of dexamethasone-induced insulin resistance in healthy humans. JClin Endocrinol Metab 1994, 79(4):1063-1069.
16. Beard J.C., Halter J.B., Best J.D., Pfeifer M.A., Porte D. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol Endocrinol Metab 1984, 247(5):E592-E596.
17. Bunger C.M., Tiefenbach B., Jahnke A., Gerlach C., Freier T., Schmitz K.P., et al. Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids. Biomaterials 2005, 26(15):2353-2360.
18. Ricci M., Blasi P., Giovagnoli S., Rossi C., Macchiarulo G., Luca G., et al. Ketoprofen controlled release from composite microcapsules for cell encapsulation: effecton post-transplant acute inflammation. JControl Release 2005, 107(3):395-407.
19. Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C., Luca G., et al. Preparation and invitro and invivo characterization of composite microcapsules for cell encapsulation. Int J Pharm 2006, 324(1):27-36.
20. Murua A., Herran E., Orive G., Igartua M., Blanco F.J., Pedraz J.L., et al. Design of a composite drug delivery system to prolong functionality of cell-based scaffolds. Int J Pharm 2011, 407(1):142-150.
21. Dang T.T., Bratlie K.M., Bogatyrev S.R., Chen X.Y., Langer R., Anderson D.G. Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response. Biomaterials 2011, 32(19):3364-4470.
22. Liu W.F., Ma M., Bratlie K.M., Dang T.T., Langer R., Anderson D.G. Real-time invivo detection of biomaterial-induced reactive oxygen species. Biomaterials 2011, 32(7):1796-1801.
23. Bratlie K.M., Dang T.T., Lyle S., Nahrendorf M., Weissleder R., Langer R., et al. Rapidbiocompatibility analysis of materials via invivo fluorescence imaging ofmouse models. Plos One 2010, 5(5):e10032. 10.1371/journal.pone.0010032.
24. Rhen T., Cidlowski J.A. Anti-inflammatory action of glucocorticoids: new mechanisms for old drugs. NEngl J Med 2005, 353(16):1711.
25. Attur M.G., Patel R., Thakker G., Vyas P., Levartovsky D., Patel P., et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE 2 production. Inflamm Res 2000, 49(1):20-26.
26. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998, 95(2):681.
27. Joe B., Vijaykumar M., Lokesh B.R. Biological properties of curcumin - cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004, 44(2):97-111.
28. Fournier E., Passirani C., Montero-Menei C.N., Benoit J.P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003, 24(19):3311-3331.
29. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev 1997, 28(1):5-24.
30. O'Sullivan E.S., Johnson A.S., Omer A., Hollister-Lock J., Bonner-Weir S., Colton C.K., et al. Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia 2010, 53(5):937-945.
31. Garg R., Adler G.K. Pharmacology of the adrenal cortex. Principles of pharmacology: the pathophysiologic basis of drug therapy 2011, 489-508. Lippincott Williams & Wilkins, Philadelphia. 3rd ed. D.E. Golan, A.H. Tashjian, E.J. Armstrong, A.W. Armstrong (Eds.).
32. Sharma S., Chopra K., Kulkarni S.K., Agrewala J.N. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 2007, 147(1):155-163.
33. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998, 47(14):78-87.
34. Hunt J.A., Williams D.F. Modification of the soft tissue response to implanted materials through the use of an anti-inflammatory drug. JMater Sci: Mater Med 1992, 3(3):160-169.
35. De Vos P., van Hoogmoed C.G., de Haan B.J., Busscher H.J. Tissue responses against immunoisolating alginate PLL capsules in the immediate post-transplant period. JBiomed Mater Res. 2002, 62(3):430-437.
36. Gotfredsen C.F., Stewart M.G., O'Shea G.M., Vose J.R., Horn T., Moody A.J. The fate of transplanted encapsulated islets in spontaneously diabetic BB/Wor rats. Diabetes Res 1990, 15(4):157.
37. Gautam S.C., Gao X., Dulchavsky S. Immunomodulation by curcumin. Adv Exp Med Biol 2007, 595:321-341.
38. Chun K.S., Keum Y.S., Han S.S., Song Y.S., Kim S.H., Surh Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 2003, 24(9):1515-1524.
39. Hong J., Bose M., Ju J., Ryu J.H., Chen X., Sang S., et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25(9):1671-1679.
40. Bhaumik S., Jyothi M.D., Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 2000, 483(1):78-82.
41. Kim G.Y., Kim K.H., Lee S.H., Yoon M.S., Lee H.J., Moon D.O., et al. Curcumin inhibitsimmunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. JImmunol 2005, 174(12):8116-8124.
42. Kim W., Fan Y.Y., Smith R., Patil B., Jayaprakasha G.K., McMurray D.N., et al. Dietary curcumin and limonin suppress CD4+ T-cell proliferation and interleukin-2 production in mice. JNutr 2009, 139(5):1042-1048.
43. De Vos P., Hamel A.F., Tatarkiewicz K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia 2002, 45(2):159-173.
44. Kanitkar M., Gokhale K., Galande S., Bhonde R.R. Novel role of curcumin in the prevention of cytokine induced islet death invitro and diabetogenesis invivo. Br J Pharmacol 2008, 155(5):702-713.
45. Kanitkar M., Bhonde R.R. Curcumin treatment enhances islet recovery by induction of heat shock response proteins, Hsp70 and heme oxygenase-1, during cryopreservation. Life Sci 2008, 82(3-4):182-189.
46. Bouhadir K.H., Lee K.Y., Alsberg E., Damm K.L., Anderson K.W., Mooney D.J. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog 2001, 17(5):945-950.
47. Uhrich K.E., Cannizzaro S.M., Langer R.S., Shakesheff K.M. Polymeric systems for controlled drug release. Chem Rev. 1999, 99(11):3181-3198.
48. Kurien B.T., Singh A., Matsumoto H., Scofield R.H. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007, 5(4):567-576.
49. Einmahl S., Zignani M., Varesio E., Heller J., Veuthey J.L., Tabatabay C., et al. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly (ortho ester). Int J Pharm 1999, 185(2):189-198.
50. Hermanson G.T. Bioconjugate techniques 2008, Elsevier. 2nd ed.
51. Ma M., Chiu A., Sahay G., Doloff J.C., Dholakia N., Thakrar R., et al. Core-shell hydrogel microcapsules for improved islets encapsulation. Adv Healthc Mater 2012, [Epub ahead of print]. 10.1002/adhm.201200341.
52. Opara E.C., Mirmalek-Sani S.-H., Khanna O., Moya M.L., Brey E.M. Design of a bioartificial pancreas. JInvestig Med 2010, 58(7):831.
53. Khanna O., Moya M.L., Greisler H.P., Opara E.C., Brey E.M. Multilayered microcapsules for the sustained-release of angiogenic proteins from encapsulated cells. Am J Surg 2010, 200(5):655-658.
54. Dang T.T., Xu Q., Bratlie K.M., O'Sullivan E.S., Chen X.Y., Langer R., et al. Microfabrication of homogenous, asymmetric cell-laden hydrogel capsules. Biomaterials 2009, 30(36):6896-6902.